e-learning
resources
European Respiratory Review
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Getting approval for new therapeutic medical devices versus drugs: are the differences justified?
Frigerio Maria
Source:
Eur Respir Rev 2016; 25: 223-226
Journal Issue:
September
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Frigerio Maria. Getting approval for new therapeutic medical devices versus drugs: are the differences justified?. Eur Respir Rev 2016; 25: 223-226
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
The issues and the controversies: are we really ready for on-demand use of ICS?
Source: Annual Congress 2013 –Inhaled corticosteroids for asthma: on-demand or continuous use?
Year: 2013
Making clinical sense of the explosion in biologics - which drug for which patient and why?
Source: International Congress 2019 – PG10 Severe asthma in adults: systematic assessment and biological treatment
Year: 2019
Application of management guidelines to the assessment of new medicines: driving us forward or holding us back?
Source: Eur Respir J 2004; 23: 793-794
Year: 2004
Prescriptions for treatment in patients with PCD: does clinical routine match recommendations?
Source: Virtual Congress 2020 – Worldwide respiratory disease across the full spectrum
Year: 2020
Evidence-based medicines for children: important implications for new therapies at all ages
Source: Eur Respir J 2006; 28: 1069-1072
Year: 2006
Acceptance criteria for intensive care: we need new definitions and legislations for futile treatment!
Source: International Congress 2017 – COPD and weaning
Year: 2017
Tuberculosis elimination, patients' lives and rational use of new drugs: revisited
Source: Eur Respir J 2016; 47: 664-667
Year: 2016
Respiratory medicines for children: current evidence, unlicensed use and research priorities
Source: Eur Respir J 2010; 35: 247-265
Year: 2010
Protocol of early mobilization and rehabilitation in critical patients using inotropic medications: Is it really safe? Our hands on practice!
Source: International Congress 2019 – Exercise and rehabilitation in patients with acute and chronic respiratory diseases
Year: 2019
Foundation doctor knowledge of inhaled devices - Are the old better than the new?
Source: International Congress 2016 – Abstracts in medical education, the web and the internet
Year: 2016
Biologics: current use and future applications for personalised therapy
Source: Virtual Congress 2021 – Wheezing illnesses along the life span
Year: 2021
Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects
Source: International Congress 2017 – In the frontline of the fight against tuberculosis
Year: 2017
Who can pay for innovative medicines?
Source: Eur Respir J 2013; 41: 495-496
Year: 2013
Preventing skin care issues associated with face masks used for domiciliary non-invasive ventilation: what do users and their carers think are the most relevant future research questions?
Source: International Congress 2019 – Treatment of chronic respiratory failure with noninvasive ventilation
Year: 2019
Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
The sustainability agenda and inhaled therapy: what do patients want?
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Do we need new antibiotics?
Source: Annual Congress 2009 - Antibiotics and the lung
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept